I. M. Markusse, G. Akdemir, L. Dirven, Y. Goekoop-ruiterman, J. Van-groenendael et al., Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled TreatmentA Randomized TrialLong-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis, Ann Intern Med, vol.164, pp.523-554, 2016.

K. Visser, . Heijde-d-van, and . Der, Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature, Ann Rheum Dis, vol.68, pp.1094-1103, 2009.

H. Tian and B. N. Cronstein, Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis, Bull NYU Hosp Jt Dis, vol.65, pp.168-73, 2007.

J. Braun, P. Kästner, P. Flaxenberg, J. Währisch, P. Hanke et al., Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial, Arthritis Rheum, vol.58, pp.73-81, 2008.

M. Schiff and P. Sadowski, Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis, Arthritis Rheumatol, 2015.

. Disponible,

N. J. Minaur, R. K. Jacoby, J. A. Cosh, G. Taylor, and J. J. Rasker, Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality, J Rheumatol Suppl, vol.69, pp.3-8, 2004.

J. S. Smolen, R. Landewé, F. C. Breedveld, M. Dougados, P. Emery et al.,

, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Ann Rheum Dis, vol.69, pp.964-75, 2010.

J. S. Smolen, R. Landewé, F. C. Breedveld, M. Buch, G. Burmester et al.,

, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, vol.73, pp.492-509, 2014.

J. S. Smolen, D. Aletaha, J. Bijlsma, F. C. Breedveld, D. Boumpas et al.,

, Treating rheumatoid arthritis to target: recommendations of an international task force, Ann Rheum Dis, vol.69, pp.631-638, 2010.

J. S. Smolen, F. C. Breedveld, G. R. Burmester, V. Bykerk, M. Dougados et al.,

, Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force, Ann Rheum Dis, vol.75, pp.3-15, 2016.

C. Barnabe, B. Martin, and W. A. Ghali, Systematic review and meta-analysis: anti-tumor necrosis factor ? therapy and cardiovascular events in rheumatoid arthritis, Arthritis Care Res, vol.63, pp.522-531, 2011.

C. Escalas, M. Dalichampt, B. Combe, B. Fautrel, F. Guillemin et al., Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort, Ann Rheum Dis, vol.71, pp.1803-1811, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00790231

C. Grigor, H. Capell, A. Stirling, A. D. Mcmahon, P. Lock et al., Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, Lancet Lond Engl, vol.364, pp.263-272, 2004.

S. Verstappen, J. Jacobs, M. J. Van-der-veen, A. Heurkens, Y. Schenk et al., Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial), Ann Rheum Dis, vol.66, pp.1443-1452, 2007.

S. Momohara, E. Inoue, K. Ikari, K. Kawamura, S. Tsukahara et al., Decrease in orthopaedic operations, including total joint replacements, in patients with rheumatoid arthritis between 2001 and 2007: data from Japanese outpatients in a single institute-based large observational cohort (IORRA), Ann Rheum Dis, vol.69, pp.312-315, 2010.

K. Visser, . Heijde-d-van, and . Der, Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature, Ann Rheum Dis, vol.68, pp.1094-1103, 2009.

O. Dell, J. R. Rohr, M. , B. Cohen, and S. , Underuse of Methotrexate (MTX) in the Treatment of

, Results of a Comprehensive Pharmaceutical Claims Analysis. Arthritis Rheumatol, Disponible sur, vol.67, 2015.

J. Gottenberg, P. Ravaud, T. Bardin, P. Cacoub, A. Cantagrel et al., Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry, Arthritis Rheum, vol.62, pp.2625-2657, 2010.

X. Mariette, J. Gottenberg, P. Ravaud, and B. Combe, Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries, Rheumatol Oxf Engl, vol.50, pp.222-231, 2011.

H. Radner, K. Yoshida, I. Hmamouchi, M. Dougados, J. S. Smolen et al., Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study, J Rheumatol, vol.42, pp.1099-104, 2015.

P. Emery, C. Solem, I. Majer, J. C. Cappelleri, and M. Tarallo, A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization

, Rheumatol Int, vol.35, pp.1837-1886, 2015.

A. Saraux, V. Devauchelle-pensec, L. Engerran, and R. M. Flipo, Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey, J Rheumatol, vol.33, pp.1258-65, 2006.

L. Idolazzi, S. Adami, R. Capozza, G. Bianchi, A. Cozzolongo et al., Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study, Clin Exp Rheumatol, vol.33, pp.895-904, 2015.

A. Aga, E. Lie, T. Uhlig, I. C. Olsen, A. Wierød et al., Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study, Ann Rheum Dis, vol.74, pp.381-389, 2000.

J. Durán, M. Bockorny, D. Dalal, M. Lavalley, and D. T. Felson, Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review, Ann Rheum Dis, vol.75, pp.1595-1603, 2016.

H. Tian and B. N. Cronstein, Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis, Bull NYU Hosp Jt Dis, vol.65, pp.168-73, 2007.

D. Li, Z. Yang, P. Kang, and X. Xie, Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis, Semin Arthritis Rheum, vol.45, pp.656-62, 2016.

J. Braun, P. Kästner, P. Flaxenberg, J. Währisch, P. Hanke et al., Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial, Arthritis Rheum, vol.58, pp.73-81, 2008.

M. Hoekstra, C. Haagsma, C. Neef, J. Proost, A. Knuif et al., Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis, J Rheumatol, vol.33, pp.481-486, 2006.

P. Dhaon, S. K. Das, R. Srivastava, G. Agarwal, and A. Asthana, Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a shortterm study, Int J Rheum Dis, 2016.

M. Dahl, M. M. Gregory, and P. J. Scheuer, Methotrexate Hepatotoxicity in PsoriasisComparison of Different Dose Regimens, Br Med J, vol.1, pp.654-660, 1972.

A. Schnabel and W. L. Gross, Low-dose methotrexate in rheumatic diseases-efficacy, side effects, and risk factors for side effects, Semin Arthritis Rheum, vol.23, pp.310-337, 1994.

C. Salliot and D. Van-der-heijde, Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research, Ann Rheum Dis, vol.68, pp.1100-1104, 2009.

M. A. Lopez-olivo, H. R. Siddhanamatha, B. Shea, P. Tugwell, and G. A. Wells,